In aggregate, LLY has committed more than $11B over the last three years to expand capacity
Tirzepatide did not demonstrate detectable attenuation of weight reduction-induced decreases in sleeping or 24-h energy expenditure, but there was a reduction in respiratory exchange ratio in the tirzepatide treatment arm compared with that in the placebo arm, consistent with an increase in fat oxidation
[27] Until Phase 3 data are available and regulatory review is complete, the full clinical profile of retatrutide remains under investigation, and all findings should be interpreted with appropriate caution
It appears to stimulate the expression of growth factors and support the structural repair of axons and myelin sheaths, highlighting its potential as a therapeutic agent for various forms of neuropathy and nerve damage
Evidence + experience, side by side Ask any GLP-1 question and get instant answers backed by research and real-world experience